Long-Term Prognostic Factors after Hepatic Resection for Hepatitis C Virus-Related Hepatocellular Carcinoma, with a Special Reference to Viral Status

被引:19
作者
Koda, Masaki [1 ]
Tanaka, Shogo [1 ]
Takemura, Shigekazu [1 ]
Shinkawa, Hiroji [1 ]
Kinoshita, Masahiko [1 ]
Hamano, Genya [1 ]
Ito, Tokuji [1 ]
Kawada, Norifumi [2 ]
Shibata, Toshihiko [1 ]
Kubo, Shoji [1 ]
机构
[1] Osaka City Univ, Grad Sch Med, Dept Hepatobiliary Pancreat Surg, Osaka, Japan
[2] Osaka City Univ, Grad Sch Med, Dept Hepatol, Osaka, Japan
基金
日本学术振兴会;
关键词
Hepatocellular carcinoma; Hepatitis C; Interferon; Surgery; Sustained virological response; SUSTAINED VIROLOGICAL RESPONSE; INTERFERON THERAPY; RISK-FACTORS; CLINICOPATHOLOGICAL FEATURES; POSTOPERATIVE RECURRENCE; INTRAHEPATIC RECURRENCE; 10-YEAR SURVIVAL; LIVER RESECTION; PLUS RIBAVIRIN; GREATER-THAN-10; YEARS;
D O I
10.1159/000486902
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although studies have reported on long-term (10-year) survival after hepatic resection for hepatocellular carcinoma (HCC), they did not focus on patients with hepatitis C virus (HCV)-related HCC, and the contribution of antiviral therapy to long-term survival (especially >= 15 years) has not been adequately examined. We investigated the long-term outcome after hepatic resection for HCV-related HCC, including the effects of interferon (IFN) therapy, and the changes in prognostic factors according to postoperative duration. Methods: The data of 207 patients who underwent hepatic resection for HCV-related HCC between January 1992 and December 2001 were retrospectively reviewed. We investigated the disease- free and overall survival rates after surgery and analyzed the prognostic factors at 5, 10, and 15 years postoperatively. Results: The proportion of patients who survived at 5, 10, and 15 years after hepatic resection was 52% (n = 107), 18% (n = 38), and 9% (n = 19). The overall survival rate was significantly higher in patients who achieved sustained virological response (SVR) with IFN therapy than in those without SVR. Tumor-related factors such as multiple tumor, microscopic vascular invasion, and a high indocyanine green retention rate at 15 min (ICGR15) were unfavorable prognostic factors for 5-year survival. Conversely, a low ICGR15 and SVR were favorable prognostic factors at 10 years, and SVR alone was a favorable prognostic factor at 15 years postoperatively; no tumor-related factors were prognostic factors at 10 and 15 years postoperatively. Conclusion: The prognostic factors varied according to the duration after hepatic resection for HCV-related HCC. Tumor-related factors were unfavorable prognostic factors in the early postoperative period, whereas SVR and good liver function were favorable prognostic factors at 10 and 15 years postoperatively. Achievement of SVR with IFN therapy is essential for long-term (>= 15 years) survival after hepatic resection for HCV-related HCC. (C) 2018 S. Karger AG, Basel
引用
收藏
页码:261 / 276
页数:16
相关论文
共 56 条
[1]   The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma [J].
Ang, Soo Fan ;
Ng, Elizabeth Shu-Hui ;
Li, Huihua ;
Ong, Yu-Han ;
Choo, Su Pin ;
Ngeow, Joanne ;
Toh, Han Chong ;
Lim, Kiat Hon ;
Yap, Hao Yun ;
Tan, Chee Kiat ;
Ooi, London Lucien Peng Jin ;
Chung, Alexander Yaw Fui ;
Chow, Pierce Kah Hoe ;
Foo, Kian Fong ;
Tan, Min-Han ;
Cheow, Peng Chung .
PLOS ONE, 2015, 10 (04)
[2]  
[Anonymous], CANC STAGING MANUAL
[3]  
[Anonymous], J GASTROENTEROL
[4]  
Belghiti J., 2000, HPB, V2, P333, DOI DOI 10.1016/S1365-182X(17)30755-4
[5]   Surgical Treatment of Hepatocellular Carcinoma in North America: Can Hepatic Resection Still Be Justified? [J].
Chapman, William C. ;
Klintmalm, Goran ;
Hemming, Alan ;
Vachharajani, Neeta ;
Doyle, Maria B. Majella ;
DeMatteo, Ron ;
Zaydfudim, Victor ;
Chung, Haniee ;
Cavaness, Keith ;
Goldstein, Robert ;
Zendajas, Ivan ;
Melstrom, Laleh G. ;
Nagorney, David ;
Jarnagin, William .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2015, 220 (04) :628-637
[6]   Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease [J].
Charlton, Michael ;
Everson, Gregory T. ;
Flamm, Steven L. ;
Kumar, Princy ;
Landis, Charles ;
Brown, Robert S., Jr. ;
Fried, Michael W. ;
Terrault, Norah A. ;
O'Leary, Jacqueline G. ;
Vargas, Hugo E. ;
Kuo, Alexander ;
Schiff, Eugene ;
Sulkowski, Mark S. ;
Gilroy, Richard ;
Watt, Kymberly D. ;
Brown, Kimberly ;
Kwo, Paul ;
Pungpapong, Surakit ;
Korenblat, Kevin M. ;
Muir, Andrew J. ;
Teperman, Lewis ;
Fontana, Robert J. ;
Denning, Jill ;
Arterburn, Sarah ;
Dvory-Sobol, Hadas ;
Brandt-Sarif, Theo ;
Pang, Phillip S. ;
McHutchison, John G. ;
Reddy, K. Rajender ;
Afdhal, Nezam .
GASTROENTEROLOGY, 2015, 149 (03) :649-659
[7]  
DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629
[8]   Interferon-β plus ribavirin for patients with hepatitis C virus genotype 1:: a randomised pilot trial [J].
Enomoto, M ;
Tamori, A ;
Kawada, N ;
Jomura, H ;
Nishiguchi, S ;
Saibara, T ;
Onishi, S ;
Mochida, S ;
Fujiwara, K .
GUT, 2006, 55 (01) :139-140
[9]   Effects of ribavirin combined with interferon-α2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads [J].
Enomoto, M ;
Nishiguchi, S ;
Kohmoto, M ;
Tamori, A ;
Habu, D ;
Takeda, T ;
Seki, S ;
Shiomi, S .
JOURNAL OF VIRAL HEPATITIS, 2004, 11 (05) :448-454
[10]  
Enomoto M, 2002, AM J GASTROENTEROL, V97, P420